- Home
- CXAI vs GDTC Comparison
CXAI vs GDTC Comparison
Compare CXAI & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CXAI
- GDTC
- Stock Information
- Founded
- CXAI N/A
- GDTC 2018
- Country
- CXAI United States
- GDTC Singapore
- Employees
- CXAI N/A
- GDTC N/A
- Industry
- CXAI EDP Services
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- CXAI Technology
- GDTC Health Care
- Exchange
- CXAI Nasdaq
- GDTC Nasdaq
- Market Cap
- CXAI 22.4M
- GDTC 28.0M
- IPO Year
- CXAI N/A
- GDTC 2023
- Fundamental
- Price
- CXAI $1.02
- GDTC $2.10
- Analyst Decision
- CXAI
- GDTC Buy
- Analyst Count
- CXAI 0
- GDTC 1
- Target Price
- CXAI N/A
- GDTC $5.00
- AVG Volume (30 Days)
- CXAI 493.4K
- GDTC 5.7K
- Earning Date
- CXAI 08-11-2025
- GDTC 01-01-0001
- Dividend Yield
- CXAI N/A
- GDTC N/A
- EPS Growth
- CXAI N/A
- GDTC N/A
- EPS
- CXAI N/A
- GDTC N/A
- Revenue
- CXAI $6,548,000.00
- GDTC $368,838.00
- Revenue This Year
- CXAI N/A
- GDTC $5.37
- Revenue Next Year
- CXAI $60.00
- GDTC N/A
- P/E Ratio
- CXAI N/A
- GDTC N/A
- Revenue Growth
- CXAI N/A
- GDTC N/A
- 52 Week Low
- CXAI $0.76
- GDTC $1.20
- 52 Week High
- CXAI $3.76
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- CXAI 51.50
- GDTC 44.67
- Support Level
- CXAI $0.95
- GDTC $2.08
- Resistance Level
- CXAI $1.07
- GDTC $2.31
- Average True Range (ATR)
- CXAI 0.06
- GDTC 0.11
- MACD
- CXAI 0.01
- GDTC -0.00
- Stochastic Oscillator
- CXAI 61.36
- GDTC 12.18
About CXAI CXApp Inc.
CXApp Inc is a provider of AI-powered employee experience solutions, delivering enterprise-grade software that enhances workplace engagement, productivity, and operational efficiency. The company's flagship product, the CXAI Platform, provides a comprehensive suite of tools designed to empower employees and enable organizations to create smarter workplaces. The product's key components include CXAI Apps, CXAI BTS, and CXAI-VU. The company generates the majority of its revenue from Licenses.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.